Kenichi Makishima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kenichi Makishima has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Mamiko Sakata-Yanagimoto
Department of Hematology, University of Tsukuba Hospital, Tsukuba, Japan
8 shared publications - Yoshiaki Abe
Department of Hematology, University of Tsukuba Hospital, Tsukuba, Japan
7 shared publications Yasuhito Suehara
Department of Hematology, University of Tsukuba Hospital, Tsukuba, Japan
6 shared publications- Sakurako Suma
Department of Hematology, University of Tsukuba Hospital, Tsukuba, Japan
5 shared publications - Shigeru Chiba
Institute of Medicine, University of Tsukuba
5 shared publications - Keiichiro Hattori
Department of Hematology Institute of Medicine University of Tsukuba Tsukuba Japan
4 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Japanese Society for Lymphoreticular Tissue Research in Journal of Clinical and Experimental Hematopathology
- Vol. 66  (1) , 69-74
Discordant lymphoma consisting of splenic marginal zone lymphoma and diffuse large B-cell lymphoma in a hepatitis B virus carrier suggests virus-associated lymphomagenesis
Discordant lymphoma (DL) is a rare entity characterized by the synchronous occurrence of two distinct lymphoma subtypes in different anatomical sites. While some DLs reflect transformation from a common progenitor, others may arise from genetically unrelated clones. Clarifying the clonal relationship is critical to understanding DL pathogenesis. Whole-exome sequencing (WES) and B-cell receptor (BCR) repertoire analysis offer valuable insights, but comprehensive genomic studies in DL remain limited. We present a 61-year-old male with hepatitis B surface antigen (HBsAg) positivity, diagnosed with SMZL from splenectomy and diffuse large B-cell lymphoma (DLBCL) from mesenteric lymph node biopsy. He achieved complete remission after R-CHOP and later relapsed with DLBCL in the cervical lymph nodes. Whole-exome sequencing revealed no shared somatic mutations between SMZL and DLBCL. BCR repertoire analysis also demonstrated distinct V-J gene usage, and cytogenetic analyses supported their independent origins. Notably, DLBCL harbored mutations in TP53, MTOR, and BCL6 rearrangement alterations previously associated with hepatitis B virus (HBV)-associated lymphomas. Our multi-platform analysis supports the clonal independence of SMZL and DLBCL in this patient, suggesting that these two lymphomas arose independently despite developing concurrently. Chronic antigen stimulation and genomic integration from HBV may have contributed to dual lymphomagenesis through separate pathways. This case illustrates the potential role of HBV in driving distinct yet simultaneous B-cell neoplasms.
- 1 January 2026
- Published by Japanese Society for Lymphoreticular Tissue Research in Journal of Clinical and Experimental Hematopathology
- Vol. 66  (1) , 69-74
Open AccessDiscordant lymphoma consisting of splenic marginal zone lymphoma and diffuse large B-cell lymphoma in a hepatitis B virus carrier suggests virus-associated lymphomagenesis
Discordant lymphoma (DL) is a rare entity characterized by the synchronous occurrence of two distinct lymphoma subtypes in different anatomical sites. While some DLs reflect transformation from a common progenitor, others may arise from genetically unrelated clones. Clarifying the clonal relationship is critical to understanding DL pathogenesis. Whole-exome sequencing (WES) and B-cell receptor (BCR) repertoire analysis offer valuable insights, but comprehensive genomic studies in DL remain limited. We present a 61-year-old male with hepatitis B surface antigen (HBsAg) positivity, diagnosed with SMZL from splenectomy and diffuse large B-cell lymphoma (DLBCL) from mesenteric lymph node biopsy. He achieved complete remission after R-CHOP and later relapsed with DLBCL in the cervical lymph nodes. Whole-exome sequencing revealed no shared somatic mutations between SMZL and DLBCL. BCR repertoire analysis also demonstrated distinct V-J gene usage, and cytogenetic analyses supported their independent origins. Notably, DLBCL harbored mutations in TP53, MTOR, and BCL6 rearrangement alterations previously associated with hepatitis B virus (HBV)-associated lymphomas. Our multi-platform analysis supports the clonal independence of SMZL and DLBCL in this patient, suggesting that these two lymphomas arose independently despite developing concurrently. Chronic antigen stimulation and genomic integration from HBV may have contributed to dual lymphomagenesis through separate pathways. This case illustrates the potential role of HBV in driving distinct yet simultaneous B-cell neoplasms.
- Open Access
- 31 March 2025
- Published by Springer Nature in Leukemia
- Vol. 39  (5) , 1184-1195
Discrete genetic subtypes and tumor microenvironment signatures correlate with peripheral T-cell lymphoma outcomes
Peripheral T-cell lymphoma (PTCL) exhibits a diverse clinical spectrum, necessitating methods to categorize patients based on genomic abnormalities or tumor microenvironment (TME) profiles. We conducted an integrative multiomics study in 129 PTCL patients, performing whole-exome sequencing and identifying three genetic subtypes: C1, C2, and C3. C2 was characterized by loss of tumor suppressor genes and chromosomal instability, while C1 and C3 shared T follicular helper (TFH)-related genomic alterations, with C3 also showing a high incidence of IDH2 mutations and chromosome 5 gain. Compared to C1, survival was significantly worse in C2 (HR 2.52; 95% CI, 1.37â4.63) and C3 (HR 2.14; 95% CI, 1.17â3.89). We also estimated the proportions of immune cell fractions from the bulk RNA sequencing data using CIBERSORTx and classified TME signatures into the following hierarchical clusters: TME1 (characterized by increased B and TFH cells), TME2 (macrophages), and TME3 (activated mast cells). TME2 was associated with shorter survival (HR 3.4; 95% CI, 1.6â7.5) and was more frequent in C2 (64.3%) than in C1 (7.7%), whereas C1 had more TME3 signatures (80.8% vs. 28.6%). These findings highlight a significant relationship between genetic subtypes and TME signatures in PTCL, with important implications for clinical prognosis.
- 31 March 2025
- Published by Springer Nature in Leukemia
- Vol. 39  (5) , 1184-1195
Open AccessDiscrete genetic subtypes and tumor microenvironment signatures correlate with peripheral T-cell lymphoma outcomes
Peripheral T-cell lymphoma (PTCL) exhibits a diverse clinical spectrum, necessitating methods to categorize patients based on genomic abnormalities or tumor microenvironment (TME) profiles. We conducted an integrative multiomics study in 129 PTCL patients, performing whole-exome sequencing and identifying three genetic subtypes: C1, C2, and C3. C2 was characterized by loss of tumor suppressor genes and chromosomal instability, while C1 and C3 shared T follicular helper (TFH)-related genomic alterations, with C3 also showing a high incidence of IDH2 mutations and chromosome 5 gain. Compared to C1, survival was significantly worse in C2 (HR 2.52; 95% CI, 1.37â4.63) and C3 (HR 2.14; 95% CI, 1.17â3.89). We also estimated the proportions of immune cell fractions from the bulk RNA sequencing data using CIBERSORTx and classified TME signatures into the following hierarchical clusters: TME1 (characterized by increased B and TFH cells), TME2 (macrophages), and TME3 (activated mast cells). TME2 was associated with shorter survival (HR 3.4; 95% CI, 1.6â7.5) and was more frequent in C2 (64.3%) than in C1 (7.7%), whereas C1 had more TME3 signatures (80.8% vs. 28.6%). These findings highlight a significant relationship between genetic subtypes and TME signatures in PTCL, with important implications for clinical prognosis.
- Open Access
- 17 September 2024
- Published by Wiley in Cancer Science
- Vol. 115  (11) , 3788-3794
Genetic profiles and clinical features in subcutaneous panniculitisâlike Tâcell lymphomas
Subcutaneous panniculitisâlike Tâcell lymphoma (SPTCL) is a rare peripheral Tâcell lymphoma characterized by cutaneous lesions and immunologic manifestations. The fiveâyear survival rate of SPTCL has been reported to be over 80%, indicating a favorable prognosis. Recent studies have uncovered recurrent germline variants in HAVCR2, encoding an immunomodulator. In this study, we integrated wholeâexome sequencing data from 60 samples collected from 36 SPTCL patients, encompassing six patients of our cohort and 30 patients of publicly available data. We identified 138 somatic mutations in skin tumors of 24 patients and HAVCR2 germline mutations in 23 of 29 patients. HAVCR2 p.Tyr82Cys mutations were identified in four of six Japanese patients. During the clinical courses of four patients, cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone were administered to all patients, but it resulted in incomplete responses in all four patients. However, disease conditions of all patients remained stable with additional treatment, including autologous peripheral blood stem cell transplantation. Over a 7.5âyear median followâup, one patient developed autoimmuneârelated diseases, while one developed other hematological malignancy, resulting in death. To our knowledge, this is the first report of recurrent HAVCR2 germline mutations in Japanese patients, suggesting the necessity for longâterm followâup.
- 17 September 2024
- Published by Wiley in Cancer Science
- Vol. 115  (11) , 3788-3794
Open AccessGenetic profiles and clinical features in subcutaneous panniculitisâlike Tâcell lymphomas
Subcutaneous panniculitisâlike Tâcell lymphoma (SPTCL) is a rare peripheral Tâcell lymphoma characterized by cutaneous lesions and immunologic manifestations. The fiveâyear survival rate of SPTCL has been reported to be over 80%, indicating a favorable prognosis. Recent studies have uncovered recurrent germline variants in HAVCR2, encoding an immunomodulator. In this study, we integrated wholeâexome sequencing data from 60 samples collected from 36 SPTCL patients, encompassing six patients of our cohort and 30 patients of publicly available data. We identified 138 somatic mutations in skin tumors of 24 patients and HAVCR2 germline mutations in 23 of 29 patients. HAVCR2 p.Tyr82Cys mutations were identified in four of six Japanese patients. During the clinical courses of four patients, cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone were administered to all patients, but it resulted in incomplete responses in all four patients. However, disease conditions of all patients remained stable with additional treatment, including autologous peripheral blood stem cell transplantation. Over a 7.5âyear median followâup, one patient developed autoimmuneârelated diseases, while one developed other hematological malignancy, resulting in death. To our knowledge, this is the first report of recurrent HAVCR2 germline mutations in Japanese patients, suggesting the necessity for longâterm followâup.
- Open Access
- 27 November 2023
- Published by Springer Nature in Leukemia
- Vol. 38  (2) , 340-350
Tumor heterogeneity and immune-evasive T follicular cell lymphoma phenotypes at single-cell resolution
T follicular helper (TFH) cell lymphomas (TFHLs) are characterized by TFH-like properties and accompanied by substantial immune-cell infiltration into tumor tissues. Nevertheless, the comprehensive understanding of tumor-cell heterogeneity and immune profiles of TFHL remains elusive. To address this, we conducted single-cell transcriptomic analysis on 9 lymph node (LN) and 16 peripheral blood (PB) samples from TFHL patients. Tumor cells were divided into 5 distinct subclusters, with significant heterogeneity observed in the expression levels of TFH markers. Copy number variation (CNV) and trajectory analyses indicated that the accumulation of CNVs, together with gene mutations, may drive the clonal evolution of tumor cells towards TFH-like and cell proliferation phenotypes. Additionally, we identified a novel tumor-cell-specific marker, PLS3. Notably, we found a significant increase in exhausted CD8+ T cells with oligoclonal expansion in TFHL LNs and PB, along with distinctive immune evasion characteristics exhibited by infiltrating regulatory T, myeloid, B, and natural killer cells. Finally, in-silico and spatial cell-cell interaction analyses revealed complex networking between tumor and immune cells, driving the formation of an immunosuppressive microenvironment. These findings highlight the remarkable tumor-cell heterogeneity and immunoevasion in TFHL beyond previous expectations, suggesting potential roles in treatment resistance.
- 27 November 2023
- Published by Springer Nature in Leukemia
- Vol. 38  (2) , 340-350
Open AccessTumor heterogeneity and immune-evasive T follicular cell lymphoma phenotypes at single-cell resolution
T follicular helper (TFH) cell lymphomas (TFHLs) are characterized by TFH-like properties and accompanied by substantial immune-cell infiltration into tumor tissues. Nevertheless, the comprehensive understanding of tumor-cell heterogeneity and immune profiles of TFHL remains elusive. To address this, we conducted single-cell transcriptomic analysis on 9 lymph node (LN) and 16 peripheral blood (PB) samples from TFHL patients. Tumor cells were divided into 5 distinct subclusters, with significant heterogeneity observed in the expression levels of TFH markers. Copy number variation (CNV) and trajectory analyses indicated that the accumulation of CNVs, together with gene mutations, may drive the clonal evolution of tumor cells towards TFH-like and cell proliferation phenotypes. Additionally, we identified a novel tumor-cell-specific marker, PLS3. Notably, we found a significant increase in exhausted CD8+ T cells with oligoclonal expansion in TFHL LNs and PB, along with distinctive immune evasion characteristics exhibited by infiltrating regulatory T, myeloid, B, and natural killer cells. Finally, in-silico and spatial cell-cell interaction analyses revealed complex networking between tumor and immune cells, driving the formation of an immunosuppressive microenvironment. These findings highlight the remarkable tumor-cell heterogeneity and immunoevasion in TFHL beyond previous expectations, suggesting potential roles in treatment resistance.
- Open Access
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142  (Supplement) , 430
Distinct Minor Neoplastic Follicular T-Cell Subsets Dictate Lymphoma Fates through Functional Specialization
Disclosures. Yoshida:Bristol Myers Squibb: Research Funding; Novartis Pharmaceuticals: Honoraria. Matsue:AstraZeneca: Research Funding. Chiba:Eisai Co., Ltd.: H
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142  (Supplement) , 430
Open AccessDistinct Minor Neoplastic Follicular T-Cell Subsets Dictate Lymphoma Fates through Functional Specialization
Disclosures. Yoshida:Bristol Myers Squibb: Research Funding; Novartis Pharmaceuticals: Honoraria. Matsue:AstraZeneca: Research Funding. Chiba:Eisai Co., Ltd.: H
- Open Access
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142  (Supplement) , 5608
Investigation of Clonal Hematopoiesis in New Japanese Cohort
Disclosures. Chiba:Eisai Co., Ltd.: Honoraria; Bayer Pharma: Honoraria; Chugai Pharmaceutical: Honoraria; Kyowa Kirin: Research Funding; Astellas: Research Fund
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142  (Supplement) , 5608
Open AccessInvestigation of Clonal Hematopoiesis in New Japanese Cohort
Disclosures. Chiba:Eisai Co., Ltd.: Honoraria; Bayer Pharma: Honoraria; Chugai Pharmaceutical: Honoraria; Kyowa Kirin: Research Funding; Astellas: Research Fund
- Open Access
- 8 August 2023
- Published by Wolters Kluwer Health in HemaSphere
- Vol. 7  (S3) , e1725993
S237: THE GENETIC SUBTYPES AND THE TUMOR MICROENVIRONMENT SIGNATURES ARE ASSOCIATED WITH DISTINCT OUTCOMES IN PERIPHERAL T-CELL LYMPHOMA
- 8 August 2023
- Published by Wolters Kluwer Health in HemaSphere
- Vol. 7  (S3) , e1725993
Open AccessS237: THE GENETIC SUBTYPES AND THE TUMOR MICROENVIRONMENT SIGNATURES ARE ASSOCIATED WITH DISTINCT OUTCOMES IN PERIPHERAL T-CELL LYMPHOMA
- Open Access
- 3 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140  (18) , 1937-1950
Clonal germinal center B cells function as a niche for T-cell lymphoma
Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes the development of T follicular helper (TFH)-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development using mouse models and human samples. Among the 2 mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre Ă Tet2flox/flox Ă G17V RHOA transgenic mice) spontaneously developed AITL for approximately up to a year, while mice lacking Tet2 only in the T cells (Cd4-Cre Ă Tet2flox/flox Ă G17V RHOA transgenic mice) did not. Therefore, Tet2-deficient immune cells function as a niche for AITL development. Single-cell RNA-sequencing (scRNA-seq) of >50 000 cells from mouse and human AITL samples revealed significant expansion of aberrant B cells, exhibiting properties of activating light zone (LZ)-like and proliferative dark zone (DZ)-like germinal center B (GCB) cells. The GCB cells in AITL clonally evolved with recurrent mutations in genes related to core histones. In silico network analysis using scRNA-seq data identified Cd40âCd40lg as a possible mediator of GCB and tumor cell cluster interactions. Treatment of AITL model mice with anti-Cd40lg inhibitory antibody prolonged survival. The genes expressed in aberrantly expanded GCB cells in murine tumors were also broadly expressed in the B-lineage cells of TET2-mutant human AITL. Therefore, ACH-derived GCB cells could undergo independent clonal evolution and support the tumorigenesis in AITL via the CD40âCD40LG axis.
- 3 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140  (18) , 1937-1950
Open AccessClonal germinal center B cells function as a niche for T-cell lymphoma
Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes the development of T follicular helper (TFH)-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development using mouse models and human samples. Among the 2 mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre Ă Tet2flox/flox Ă G17V RHOA transgenic mice) spontaneously developed AITL for approximately up to a year, while mice lacking Tet2 only in the T cells (Cd4-Cre Ă Tet2flox/flox Ă G17V RHOA transgenic mice) did not. Therefore, Tet2-deficient immune cells function as a niche for AITL development. Single-cell RNA-sequencing (scRNA-seq) of >50 000 cells from mouse and human AITL samples revealed significant expansion of aberrant B cells, exhibiting properties of activating light zone (LZ)-like and proliferative dark zone (DZ)-like germinal center B (GCB) cells. The GCB cells in AITL clonally evolved with recurrent mutations in genes related to core histones. In silico network analysis using scRNA-seq data identified Cd40âCd40lg as a possible mediator of GCB and tumor cell cluster interactions. Treatment of AITL model mice with anti-Cd40lg inhibitory antibody prolonged survival. The genes expressed in aberrantly expanded GCB cells in murine tumors were also broadly expressed in the B-lineage cells of TET2-mutant human AITL. Therefore, ACH-derived GCB cells could undergo independent clonal evolution and support the tumorigenesis in AITL via the CD40âCD40LG axis.
- Open Access
- 21 November 2021
- Published by Wiley in Cancer Science
- Vol. 113  (1) , 362-364
Intratumor heterogeneity of lymphoma identified by multiregion sequencing of autopsy samples
- 21 November 2021
- Published by Wiley in Cancer Science
- Vol. 113  (1) , 362-364
Open AccessIntratumor heterogeneity of lymphoma identified by multiregion sequencing of autopsy samples